University of Florida/Sid Martin Biotechnology Institute Announces Addition Of Vaccine Technology Startup Curtiss Healthcare, Inc.

Curtiss Healthcare has raised $1.4 million seed capital to further the development of unique vaccines against infectious disease agents. University of Florida Professor Roy Curtiss III, PhD, is co-founder of the company.

ALACHUA, FL – June 20, 2016 – UF/Sid Martin Biotechnology Institute, the leading biotechnology incubator at the University of Florida, announced a new vaccine technology startup, Curtiss Healthcare, Inc.®, has been admitted into its bio-incubation program located in Alachua. The Institute offers startups collaborative, open laboratory workspace combined with financial, technical and human resources to nuture startups’ growth and success.

Curtiss Healthcare, Inc. - Novel Vaccine Technology

An innovator with proprietary vaccine technology, Curtiss Healthcare was founded in 2015 to commercialize a platform to develop new vaccines to help make the world a safer place. The company’s technologies improve food quality and safety and help treat and prevent serious infections in animals and humans. The intellectual property portfolio aggregates groundbreaking technology from Dr. Roy Curtiss’s academic work at several Universities including the University of Florida. Curtiss Healthcare has raised $1.4 million in seed capital.

Global Health Priority

Infectious diseases are responsible for approximately 25% of global mortality, especially in children aged younger than 5 years.¹ The global market for human vaccines against infectious diseases is estimated to grow to an estimated value of USD 61 billion in 2020.² The worldwide animal vaccines market is expected to cross the $8.6 billion mark by 2018.³

Intellectual Property

Curtiss Healthcare possesses and controls all the intellectual property for an innovative and superior live recombinant attenuated Salmonella vaccine (RASV) vector platform that can be used to develop vaccines against any bacterial, viral or parasite pathogen in any animal species or humans, requiring only the identity of the protective antigens. Total safety and efficacy in inducing long-lived protective mucosal, systemic and cellular immunities are achieved by using the company’s patented process.

Mark Long, Director of the UF/Sid Martin Biotechnology Institute, discussed the admission of Curtiss to the Institute, “Curtiss Healthcare will be an asset to our growing family of companies here at the Sid Martin Biotechnology Institute. With the aggressive Intellectual Property portfolio and outstanding research capacity of Curtiss, the company is poised for takeoff in the field of vaccine development.”

Curtiss Healthcare, Inc.

Thomas Bigger, Curtiss President and CEO said, “We are very pleased to be part of the Sid Martin Biotechnology Institute and are looking forward to taking full advantage of the strategic opportunities and support services that exist here.” The new startup was admitted to the Institute’s bio-business program through the fast track admissions process. Prospective startups may submit an inquiry form through the Institute’s website and management will make contact to walk them through the admissions process.

About UF/Sid Martin Biotechnology Institute

UF/Sid Martin Biotechnology Institute is the leading biotechnology incubator headquartered at the University of Florida in Alachua, Florida at Progress Park. The Institute has been honored with national and international awards for incubator excellence and achievements in technology commercialization, funding access, job creation and technology-based economic development. It is dedicated to mentoring and accelerating the growth of innovative early-stage bioscience and biotechnology companies, and supporting the economic growth of the North Central Florida region. For more information, visit

About Curtiss Healthcare, Inc.®

Curtiss Healthcare is an early stage start-up company based in Gainesville, Florida, solely engaged in the development and commercialization of innovative and superior live recombinant attenuated Salmonella vaccine (RASV) vector platform that can be used to develop vaccines against any bacterial, viral or parasite pathogen in any animal species or humans. The technology was created by Co-Founder Roy Curtiss III, PhD, University Florida Professor, Department of Infectious Diseases and Pathology, College of Veterinary Medicine.

Back to news